Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
Healthtrust
Covington
Novartis
Fish and Richardson
Fuji
McKesson
Mallinckrodt
Citi

Generated: January 21, 2018

DrugPatentWatch Database Preview

MOZOBIL Drug Profile

« Back to Dashboard

Which patents cover Mozobil, and when can generic versions of Mozobil launch?

Mozobil is a drug marketed by Genzyme and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has seventy-two patent family members in twenty-nine countries.

The generic ingredient in MOZOBIL is plerixafor. There are five drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the plerixafor profile page.
Summary for MOZOBIL
International Patents:72
US Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: 2
Bulk Api Vendors: 77
Clinical Trials: 75
Patent Applications: 747
Drug Prices:see details
DailyMed Link:MOZOBIL at DailyMed
Drug patent expirations by year for MOZOBIL
Pharmacology for MOZOBIL

US Patents and Regulatory Information for MOZOBIL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Genzyme MOZOBIL plerixafor SOLUTION;SUBCUTANEOUS 022311-001 Dec 15, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Genzyme MOZOBIL plerixafor SOLUTION;SUBCUTANEOUS 022311-001 Dec 15, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Genzyme MOZOBIL plerixafor SOLUTION;SUBCUTANEOUS 022311-001 Dec 15, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for MOZOBIL
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Injection 24 mg/1.2 mL vials (20 mg/mL) ➤ Subscribe 12/17/2012

Non-Orange Book US Patents for MOZOBIL

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,583,131 Aromatic-linked polyamine macrocyclic compounds with anti-HIV activity ➤ Subscribe
7,169,750 Methods to mobilize progenitor/stem cells ➤ Subscribe
7,935,692 Methods to mobilize progenitor/stem cells ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for MOZOBIL

Supplementary Protection Certificates for MOZOBIL

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB10/004 United Kingdom ➤ Subscribe PRODUCT NAME: PLERIXAFOR IN ALL FORMS PROTECTED BY THE BASIC PATENT; REGISTERED: UK EU/1/09/537/001 20090731; REASON FOR LAPSE: SURRENDERED
00425 Netherlands ➤ Subscribe PRODUCT NAME: PLERIXAFOR, DESGEWENST IN DE VORM VAN EEN NIET-TOXISCH ZUURADDITIE ZOUT OF METAALCOMPLEX; REGISTRATION NO/DATE: EU/1/09/537/001 20090731
00537 Netherlands ➤ Subscribe PRODUCT NAME: PLERIXAFOR IN ELKE DOOR HET BASISOCTROOI BESCHERMDE VORM; REGISTRATION NO/DATE: EU/1/09/537/001 20090731
0537 Netherlands ➤ Subscribe PRODUCT NAME: PLERIXAFOR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF METAALCOMPLEX; REGISTRATION NO/DATE: EU/1/09/537/001 20090804
5 5011-2012 Slovakia ➤ Subscribe PRODUCT NAME: PLERIXAFOR; REGISTRATION NO/DATE: EU/1/09/537/001 20090804
0120014 00064 Estonia ➤ Subscribe PRODUCT NAME: MOZOBIL - PLERIXAFOR;REG NO/DATE: C(2009)6238 31.07.2009
033 Luxembourg ➤ Subscribe 92033, EXPIRES: 20240731
C038/2009 Ireland ➤ Subscribe SPC038/2009: 20101001, EXPIRES: 20171215
2012 00026 Denmark ➤ Subscribe
/2012 Austria ➤ Subscribe PRODUCT NAME: PLERIXAFOR, GEGEBENENFALLS ALS PHARMAZEUTISCH VERTRAEGLICHES SALZ ODER METALLKOMPLEX DAVON; REGISTRATION NO/DATE: EU/1/09/537/001 20090731
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Chinese Patent Office
McKinsey
UBS
AstraZeneca
Express Scripts
Healthtrust
Boehringer Ingelheim
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot